FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer

February 27, 2018 – On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. YS-ON-001 is a clinical-stage immuno-oncology biologic product with unique immunomodulating mechanism and broad spectrum of antitumor activity. “YS-ON-001 is an emerging immuno-oncology … (leggi tutto)